var data={"title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Whitney A High, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Jean-Claude Roujeau, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">N Franklin Adkinson, Jr, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION AND TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions, most commonly triggered by medications, characterized by extensive necrosis and detachment of the epidermis [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. According to a widely accepted classification, SJS and TEN are considered a disease continuum and are distinguished chiefly by severity, based upon the percentage of body surface involved with blisters and erosions (<a href=\"image.htm?imageKey=PEDS%2F77983\" class=\"graphic graphic_table graphicRef77983 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/2,3\" class=\"abstract_t\">2,3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SJS is the less severe condition, in which skin detachment is &lt;10 percent of the body surface (<a href=\"image.htm?imageKey=ALLRG%2F67632%7EEM%2F76141%7EEM%2F73805\" class=\"graphic graphic_picture graphicRef67632 graphicRef76141 graphicRef73805 \">picture 1A-C</a>). Mucous membranes are affected in over 90 percent of patients, usually at two or more distinct sites (ocular, oral, and genital).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TEN involves detachment of &gt;30 percent of the body surface area (BSA) (<a href=\"image.htm?imageKey=DERM%2F68458%7EDERM%2F82150%7EDERM%2F59418%7EALLRG%2F66134\" class=\"graphic graphic_picture graphicRef68458 graphicRef82150 graphicRef59418 graphicRef66134 \">picture 2A-D</a>). Mucous membranes are also involved in over 90 percent of patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">SJS/TEN</span> overlap describes patients with skin detachment of 10 to 30 percent of BSA.</p><p/><p>We will use the term <span class=\"nowrap\">&quot;SJS/TEN&quot;</span> to refer collectively to SJS, TEN, and <span class=\"nowrap\">SJS/TEN</span> overlap syndrome.</p><p>The pathogenesis, clinical manifestations, and diagnosis of <span class=\"nowrap\">SJS/TEN</span> are discussed in this topic. Treatment, prognosis, and long-term complications are discussed separately. Other drug eruptions are reviewed elsewhere. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">&quot;Acute generalized exanthematous pustulosis (AGEP)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">&quot;Fixed drug eruption&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lichenoid-drug-eruption-drug-induced-lichen-planus\" class=\"medical medical_review\">&quot;Lichenoid drug eruption (drug-induced lichen planus)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors\" class=\"medical medical_review\">&quot;Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Estimates of incidence for Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and <span class=\"nowrap\">SJS/TEN</span> overlap range from two to seven cases per million people per year [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/4-9\" class=\"abstract_t\">4-9</a>]. SJS is more common, outnumbering TEN by as much as three cases to one [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. In the United States, the estimated incidences of SJS, <span class=\"nowrap\">SJS/TEN,</span> and TEN among children between 2009 and 2012 were 5.3, 0.8, and 0.4 cases per million children per year [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>]. </p><p>The incidence of <span class=\"nowrap\">SJS/TEN</span> is much higher among human immunodeficiency virus (HIV)-infected individuals and patients with active cancer than in the general population [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/12,13\" class=\"abstract_t\">12,13</a>]. (See <a href=\"#H19\" class=\"local\">'Human immunodeficiency virus infection'</a> below and <a href=\"#H4044226447\" class=\"local\">'Malignancy'</a> below.)</p><p><span class=\"nowrap\">SJS/TEN</span> can occur in patients of any age. It is more common in women than in men, with a male to female ratio of approximately 1:2 [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. </p><p>The overall mortality rate among patients with <span class=\"nowrap\">SJS/TEN</span> is approximately 30 percent, ranging from approximately 10 percent for SJS to more than 30 percent for TEN. Mortality continues to increase up to one year after disease onset. </p><p>In a survival analysis of a large cohort of <span class=\"nowrap\">SJS/TEN</span> patients, the overall mortality rate was 23 percent at six weeks, 28 percent at three months, and 34 percent at one year [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. When distinguishing patients by severity, the mortality rates at six weeks were 12 percent for SJS, 29 percent for <span class=\"nowrap\">SJS/TEN</span> overlap, and 46 percent for TEN and increased at one year to 24 percent for SJS, 43 percent for <span class=\"nowrap\">SJS/TEN</span> overlap, and 49 percent for TEN. Older age (&gt;70 years) and presence of severe comorbidities, but not disease severity, were associated with mortality beyond three months of disease onset. (See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">ETIOLOGY</span></p><p class=\"headingAnchor\" id=\"H57294570\"><span class=\"h2\">Drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medications are the leading trigger of Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> in both adults and children. The risk of <span class=\"nowrap\">SJS/TEN</span> seems to be limited to the first eight weeks of treatment. Drugs used for a longer time are unlikely to be the cause of <span class=\"nowrap\">SJS/TEN</span>. Approximately 20 to 25 percent of cases, and probably an even higher proportion of pediatric cases, cannot be clearly attributed to a drug [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/15\" class=\"abstract_t\">15</a>].</p><p>In a large multinational case-control study including 379 cases of <span class=\"nowrap\">SJS/TEN</span> and 1505 controls, the following agents or groups of agents were most commonly implicated (<a href=\"image.htm?imageKey=DERM%2F91163\" class=\"graphic graphic_table graphicRef91163 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/16,17\" class=\"abstract_t\">16,17</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">Allopurinol</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aromatic anticonvulsants</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibacterial sulfonamides</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">Lamotrigine</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">Nevirapine</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oxicam nonsteroidal anti-inflammatory drugs (NSAIDs) </p><p/><p>In children, the medications most often associated with <span class=\"nowrap\">SJS/TEN</span> are sulfonamide antimicrobials, <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, and <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>. A weak association with <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a><span class=\"nowrap\">/paracetamol</span> has also been reported [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/18,19\" class=\"abstract_t\">18,19</a>] but remains uncertain because of frequent administration for treating what could be early symptoms of the disease (fever, burning eyes, burning mouth).</p><p>Several conventional and targeted anticancer therapies have been associated with <span class=\"nowrap\">SJS/TEN,</span> including <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>], <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>], <a href=\"topic.htm?path=afatinib-drug-information\" class=\"drug drug_general\">afatinib</a> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/22\" class=\"abstract_t\">22</a>], <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>], <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>], and immune checkpoint inhibitors (<a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>, <a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">pembrolizumab</a>, <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">nivolumab</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/25,26\" class=\"abstract_t\">25,26</a>].</p><p class=\"headingAnchor\" id=\"H57294577\"><span class=\"h2\">Mycoplasma pneumoniae infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Mycoplasma pneumoniae</em> infection is the next most common trigger of <span class=\"nowrap\">SJS/TEN,</span> particularly in children [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/27-29\" class=\"abstract_t\">27-29</a>]. A review of case series and single-case reports including 202 patients suggests that <em>M. pneumoniae</em>-associated cases may be characterized more often by moderate to severe involvement of two or more mucosal sites and sparse, or even absent, skin involvement [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/30\" class=\"abstract_t\">30</a>]. However, it is uncertain whether <em>M.&nbsp;pneumoniae</em>-associated&nbsp;mucositis (MIRM) with minimal or no skin involvement represents an atypical <span class=\"nowrap\">SJS/TEN</span> variant or is a distinct entity [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/31,32\" class=\"abstract_t\">31,32</a>]. </p><p>Between September and November 2013, an outbreak of eight pediatric cases of <em>M. pneumoniae</em>-associated <span class=\"nowrap\">SJS/TEN</span> was reported in Colorado, likely related to high levels of <em>M. pneumoniae</em> infection in the region [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/33\" class=\"abstract_t\">33</a>]. <em>M. pneumoniae</em> typing with different multilocus variable-number tandem-repeat analysis (MLVA) performed in five children found that the <span class=\"nowrap\">SJS/TEN</span> outbreak was not associated with a particular <em>M. pneumoniae</em> strain and that cases with a similar strain were not closely clustered geographically [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. At least seven more cases of SJS occurred in the same area in the first months of 2014 [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/35\" class=\"abstract_t\">35</a>]. All children had severe oropharyngeal mucositis; seven also had conjunctival involvement, and five had genital mucosal involvement. Mild skin involvement was present in all cases. </p><p class=\"headingAnchor\" id=\"H57294584\"><span class=\"h2\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In over one-third of <span class=\"nowrap\">SJS/TEN</span> cases, no cause can be identified [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/15\" class=\"abstract_t\">15</a>]. Rarely reported and debatable causes of <span class=\"nowrap\">SJS/TEN</span> include vaccinations, systemic diseases, contrast medium, external chemical exposure, herbal medicines, and foods [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/3,36-38\" class=\"abstract_t\">3,36-38</a>]. Whether drugs or drug metabolites that are present in foods as additives or contaminants are implicated in apparently idiopathic cases has not been determined [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/39\" class=\"abstract_t\">39</a>].</p><p>Cases of <span class=\"nowrap\">SJS/TEN</span> have been reported after bone marrow transplantation as a manifestation of acute graft-versus-host disease rather than as a drug-induced reaction [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/40-42\" class=\"abstract_t\">40-42</a>]. Radiotherapy in addition to treatment with antiepileptic drugs (eg, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>) or <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">amifostine</a> can trigger <span class=\"nowrap\">SJS/TEN,</span> with lesions localized predominantly at sites of radiation treatment [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>]. </p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Risk factors for Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> include human immunodeficiency virus (HIV) infection, genetic factors, underlying immunologic diseases or malignancies, and, possibly, physical factors (such as ultraviolet light or radiation therapy).</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Human immunodeficiency virus infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HIV infection have been reported to have an increased risk of drug reactions and a 100-fold higher risk of <span class=\"nowrap\">SJS/TEN</span> than the general population [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. The reasons for this susceptibility are not fully understood, although exposure to multiple medications, immune dysregulation, presence of concomitant infections, and polymorphisms of genes involved in specific drug metabolism may contribute [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/44-49\" class=\"abstract_t\">44-49</a>]. A genome-wide association study in a cohort of 151 nevirapine-hypersensitive and 182 tolerant, HIV-infected Malawian adults found that human leukocyte antigen (HLA)-C*04:01 predisposes sub-Saharan Africans to nevirapine-induced <span class=\"nowrap\">SJS/TEN</span> but not to other hypersensitivity reactions [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H4044226447\"><span class=\"h2\">Malignancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with active malignancy have an increased risk of <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/16,51,52\" class=\"abstract_t\">16,51,52</a>]. The risk is highest for patients with hematologic cancers [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/9,53\" class=\"abstract_t\">9,53</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An analysis of data from a large cohort of over 100,000 cancer patients identified from electronic health records between 2002 and 2015 identified 20 cases of confirmed <span class=\"nowrap\">SJS/TEN,</span> 30 of possible <span class=\"nowrap\">SJS/TEN,</span> and 12 with previous <span class=\"nowrap\">SJS/TEN</span>. The estimated average annual incidences were 5.7 and 14.9 per 100,000 per year for confirmed and possible cases, respectively [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>]. These incidence rates are approximately 30 to 60 times higher than in the general population. The most common trigger were antibiotics, followed by anticonvulsants and antineoplastic agents.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a case-control study including 480 validated <span class=\"nowrap\">SJS/TEN</span> patients and 1920 controls from the United Kingdom Clinical Practice Research Datalink, patients with active cancer had a two-fold increased risk of <span class=\"nowrap\">SJS/TEN</span> compared with controls (odds ratio [OR] 2.01, 95% CI 1.27-3.18) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. </p><p/><p>Whether the increased risk is due to the malignancy itself, to the frequent immunocompromised state of cancer patients, or to the increased exposure of these patients to potentially causative medications remains uncertain.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Genetic factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although several HLA haplotypes have been implicated in drug-specific susceptibility in certain ethnic groups [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/54-56\" class=\"abstract_t\">54-56</a>], genome-wide association studies on both Asian and European populations have failed to identify highly penetrant genetic risk factors associated with <span class=\"nowrap\">SJS/TEN</span> across multiple drugs [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/57\" class=\"abstract_t\">57</a>]. It is possible that multiple genetic factors with small effect size may be implicated.</p><p class=\"headingAnchor\" id=\"H2115552208\"><span class=\"h3\">HLA types</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of drug-induced <span class=\"nowrap\">SJS/TEN</span> has been associated with certain human leukocyte antigen (HLA) types (<a href=\"image.htm?imageKey=ALLRG%2F76186\" class=\"graphic graphic_table graphicRef76186 \">table 3</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HLA-B*15:02</strong> &ndash; Patients with HLA-B*15:02 phenotype are at increased risk for <span class=\"nowrap\">SJS/TEN</span> due to <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> and other aromatic anticonvulsants (eg, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/54,58\" class=\"abstract_t\">54,58</a>]. The prevalence of this allele is significant, approximately 7 to 10 percent, in patients of Asian and South Asian ancestry. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H30597917\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Role of HLA testing'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HLA-B*15:11</strong> &ndash; An association between HLA-B*15:11 and carbamazepine-induced <span class=\"nowrap\">SJS/TEN</span> has also been reported in Asian populations [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H30597917\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Role of HLA testing'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HLA-A*31:01</strong> &ndash; Genome-wide studies have also found an association between the HLA-A*31:01 allele and carbamazepine-induced severe cutaneous drug reactions, including <span class=\"nowrap\">SJS/TEN,</span> in persons of Japanese, Indian, and European ancestry [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/55,60,61\" class=\"abstract_t\">55,60,61</a>]. However, a subsequent multinational study and meta-analysis found that HLA-A*31:01 is strongly associated with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in European and Asian patients but shows a much weaker association with <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/62\" class=\"abstract_t\">62</a>]. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H30597917\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Role of HLA testing'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HLA-A*24:02</strong> &ndash; HLA-A*24:02 has been identified as an additional potential risk factor for <span class=\"nowrap\">SJS/TEN</span> induced by <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, and <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> in a southern Chinese Han population [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/63\" class=\"abstract_t\">63</a>]. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H30597917\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Role of HLA testing'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HLA-B*13:01 </strong>&ndash;<strong> </strong>HLA-B*13:01 has been found associated with dapsone-induced severe skin reactions, including predominantly DRESS, but also <span class=\"nowrap\">SJS/TEN,</span> in Thai patients [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HLA-B*58:01</strong> &ndash; A systematic review and meta-analysis found a significant association between HLA-B*58:01 and <span class=\"nowrap\">allopurinol-induced&nbsp;SJS/TEN</span> in both Asian and non-Asian populations [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/56\" class=\"abstract_t\">56</a>]. A subsequent case-control study demonstrated an association between HLA-B*58:01 and allopurinol-induced DRESS or <span class=\"nowrap\">SJS/TEN</span> in a Thai population [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"headingAnchor\" id=\"H1356230396\"><span class=\"h4\">Genetic screening</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The US Food and Drug Administration has suggested screening patients of Asian and South Asian ancestry for HLA-B*15:02 if use of <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> is under consideration [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/54,66-68\" class=\"abstract_t\">54,66-68</a>]. One consensus panel has recommended screening all carbamazepine-na&iuml;ve patients for the HLA-A*31:01 allele prior to starting treatment, regardless of race or ethnicity, since the allele is prevalent in most ethnic groups [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/69\" class=\"abstract_t\">69</a>].</p><p>The clinical utility of testing for the HLA-B*58:01 allele prior to treatment with <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a> has not been demonstrated in any population [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/70\" class=\"abstract_t\">70</a>]. However, the <a href=\"https://cpicpgx.org/&amp;token=zjLVfmxyYF0zItjS0b9hzXEA9ap4v06K9alZaoyhbSE=&amp;TOPIC_ID=2091\" target=\"_blank\" class=\"external\">Clinical Pharmacogenetics Implementation Consortium</a> (CPIC) recommends that allopurinol should not be prescribed to patients who are known carriers of&nbsp;HLA-B*58:01<em> </em>[<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/71\" class=\"abstract_t\">71</a>]. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H30597917\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Role of HLA testing'</a> and <a href=\"topic.htm?path=pharmacologic-urate-lowering-therapy-and-treatment-of-tophi-in-patients-with-gout#H18\" class=\"medical medical_review\">&quot;Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout&quot;, section on 'Allopurinol'</a>.)</p><p class=\"headingAnchor\" id=\"H2273738131\"><span class=\"h3\">Genetic polymorphisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polymorphisms in the <em>CYP2C19</em> gene, coding for a cytochrome P450 isoform, may confer an increased risk of <span class=\"nowrap\">SJS/TEN</span> following the administration of <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, or <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>]. Other <em>CYP2C</em> variants, including <em>CYP2C9*3</em>, known to be associated with reduced phenytoin clearance may be associated with an increased risk of severe cutaneous adverse reactions to phenytoin, including <span class=\"nowrap\">SJS/TEN</span> and DRESS [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/73,74\" class=\"abstract_t\">73,74</a>]. Other polymorphisms potentially associated with <span class=\"nowrap\">SJS/TEN</span> include those in the interleukin (IL)-4 receptor gene [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/75,76\" class=\"abstract_t\">75,76</a>], prostaglandin E receptor 3 gene [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/77\" class=\"abstract_t\">77</a>], and a group of genes located in the 6p21 region (<em>BAT1</em>, <em>HCP5</em>, <em>MICC</em>, and <em>PSORS1C1</em>), which are in linkage disequilibrium with HLA-B*58:01 [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/78\" class=\"abstract_t\">78</a>]. However, larger studies are needed to assess the role of genetic polymorphism in the pathogenesis of <span class=\"nowrap\">SJS/TEN</span>.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Other factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other factors that may increase the risk of <span class=\"nowrap\">SJS/TEN</span> include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High doses and rapid introduction of medications [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/17,79\" class=\"abstract_t\">17,79</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic lupus erythematosus &ndash; Patients with systemic lupus erythematosus (SLE) appear to be at an increased risk of <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/80\" class=\"abstract_t\">80</a>]. In a retrospective review of 1366 patients with <span class=\"nowrap\">SJS/TEN,</span> the prevalence of SLE was 1.2 percent, whereas the estimated prevalence in the general population is approximately 0.02 to 0.05 percent [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/81\" class=\"abstract_t\">81</a>]. However, in lupus patients, the differentiation between <span class=\"nowrap\">SJS/TEN</span> and an extreme phenotype of acute cutaneous lupus (&quot;TEN-like&quot; lupus erythematosus) may be difficult and requires accurate clinicopathologic correlation [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/81,82\" class=\"abstract_t\">81,82</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Physical stimuli, such as ultraviolet light or radiation therapy, may be cofactors in some cases [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/83-85\" class=\"abstract_t\">83-85</a>].</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathologic mechanisms that induce skin damage in Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> are incompletely understood. Early studies of the immunophenotype of lymphocytes detected in the blister fluid of <span class=\"nowrap\">SJS/TEN</span> lesions suggested a cell-mediated cytotoxic reaction against keratinocytes leading to massive apoptosis [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/86\" class=\"abstract_t\">86</a>]. Subsequent studies demonstrated that cytotoxic T cells are drug specific, human leukocyte antigen (HLA) class I restricted, and directed against the native form of the drug rather than against a reactive metabolite [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/87-89\" class=\"abstract_t\">87-89</a>]. </p><p>Drugs can stimulate the immune system by directly binding to the major histocompatibility complex (MHC) class I and the T cell receptor. This results in the clonal expansion of a population of drug-specific cytotoxic T cells that kill keratinocytes directly and indirectly through the recruitment of other cells that release soluble death mediators, including granulysin [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/90\" class=\"abstract_t\">90</a>]. (See <a href=\"topic.htm?path=drug-allergy-pathogenesis#H2\" class=\"medical medical_review\">&quot;Drug allergy: Pathogenesis&quot;, section on 'Interaction of drugs with the immune system'</a>.)</p><p>By directly binding to HLA class I peptide pouch, drugs can also alter the repertoire of peptides recognized as foreign [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/91\" class=\"abstract_t\">91</a>] and make the HLA drug complex recognized as foreign [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/92\" class=\"abstract_t\">92</a>]. This explains the severity of the reaction and its similarity to acute graft-versus-host disease. (See <a href=\"topic.htm?path=pathogenesis-of-graft-versus-host-disease\" class=\"medical medical_review\">&quot;Pathogenesis of graft-versus-host disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H54377763\"><span class=\"h2\">Mediators of keratinocyte apoptosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug-specific CD8<sup>+</sup> cytotoxic T cells, along with natural killer (NK) cells, are thought to be the major inducers of keratinocyte apoptosis [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/87,88\" class=\"abstract_t\">87,88</a>]. Various cytotoxic proteins and cytokines such as soluble Fas ligand, <span class=\"nowrap\">perforin/granzyme,</span> tumor necrosis factor (TNF)-alpha, and TNF-related apoptosis-inducing ligand (TRAIL) have been proposed as mediators for the extensive keratinocyte apoptosis in <span class=\"nowrap\">SJS/TEN</span>. However, it is now accepted that granulysin, a cytolytic protein found in cytotoxic T cells and NK cells, plays a key role in the pathogenesis of <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/93\" class=\"abstract_t\">93</a>]. </p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h3\">Granulysin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Granulysin is a cytolytic protein produced and secreted by cytotoxic T lymphocytes, NK cells, and <span class=\"nowrap\">NK/T</span> cells. The gene expression profiling of cells from five patients with SJS or TEN identified granulysin as the most highly expressed cytotoxic molecule [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/94\" class=\"abstract_t\">94</a>]. Both fluid and cells from <span class=\"nowrap\">SJS/TEN</span> patient blisters demonstrated cytotoxicity when incubated with keratinocytes, but the effect was reduced by depletion of granulysin. Control fluid or cells from patients with burns did not show such activity. The levels of granulysin in blister fluid correlated with the severity of disease. In addition, injection of granulysin from patient blisters into mouse skin caused dose-dependent blistering and necrosis.</p><p>The mechanism through which cytotoxic T lymphocytes and NK cells are stimulated to release granulysin is unknown. The results of one study suggest that the interaction between the <span class=\"nowrap\">CD94/NKG2C</span> receptor on cytotoxic T lymphocytes and HLA-E, an MHC class Ib molecule, expressed by keratinocytes in patients with SJS or TEN may promote degranulation [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/95\" class=\"abstract_t\">95</a>].</p><p class=\"headingAnchor\" id=\"H603157469\"><span class=\"h3\">Interleukin-15</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum levels of soluble interleukin (IL)-15 are increased in patients with <span class=\"nowrap\">SJS/TEN</span> and appear to be correlated with disease severity and in-hospital mortality [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/96\" class=\"abstract_t\">96</a>]. IL-15 is a widely expressed cytokine produced by many cell types, including immune cells (monocytes, macrophages, and dendritic cells) and keratinocytes [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. IL-15 has a key role in promoting and maintaining long-lasting cytotoxic T cell and NK cell responses. In in vitro models, the addition of exogenous IL-15 has been shown to increase the secretion of granulysin and, to a lesser extent, of granzyme from blister fluid cells from patients with TEN [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/96\" class=\"abstract_t\">96</a>]. In addition, in an in vitro lymphocyte transformation test designed to reveal the sensitization of T cells to a specific drug, the suppression of IL-15 signaling with a monoclonal antibody reduced the drug-mediated lymphocyte activation [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/96\" class=\"abstract_t\">96</a>]. </p><p>These findings suggest that IL-15 may have an important role in the pathogenesis of <span class=\"nowrap\">SJS/TEN</span>. However, further studies are needed to determine whether IL-15 expressed in lesional skin of <span class=\"nowrap\">SJS/TEN</span> patients elucidates the mechanisms of IL-15-driven T and NK cell responses in <span class=\"nowrap\">SJS/TEN</span>.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Other factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Soluble Fas-ligand, perforin, TNF-alpha, TRAIL, and granzyme B, which are involved in distinct nonapoptotic cell death pathways, are also found in high concentrations in the peripheral mononuclear cells and blister fluid of <span class=\"nowrap\">SJS/TEN</span> patients [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/97-99\" class=\"abstract_t\">97-99</a>]. However, elevations in these mediators are not specific to <span class=\"nowrap\">SJS/TEN</span>.</p><p class=\"headingAnchor\" id=\"H61178230\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The hallmark of Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> is the keratinocyte necrosis, ranging from partial to full-thickness necrosis of the epidermis. In early lesions, apoptotic keratinocytes are scattered in the basal layer of the epidermis, but in established lesions, full-thickness epidermal necrosis and subepidermal bullae may be seen [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. A scant, perivascular, lymphohistiocytic, inflammatory infiltrate containing a variable amount of eosinophils is present in the superficial dermis (<a href=\"image.htm?imageKey=DERM%2F93209\" class=\"graphic graphic_picture graphicRef93209 \">picture 3</a>). </p><p class=\"headingAnchor\" id=\"H57293557\"><span class=\"h1\">CLINICAL PRESENTATION</span></p><p class=\"headingAnchor\" id=\"H57293595\"><span class=\"h2\">Prodrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fever, often exceeding 39&deg;C (102.2&deg;F), and influenza-like symptoms precede by one to three days the development of mucocutaneous lesions [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/100\" class=\"abstract_t\">100</a>]. Photophobia, conjunctival itching or burning, and pain on swallowing may be early symptoms of mucosal involvement. Malaise, myalgia, and arthralgia are present in most patients.</p><p>In some patients, an exanthematous eruption can be the heralding sign of Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span>. Signs and symptoms that should alert the clinician to the possibility of <span class=\"nowrap\">SJS/TEN</span> include fever &gt;38&deg;C (100.4&deg;F), mucositis, skin tenderness, and blistering (<a href=\"image.htm?imageKey=DERM%2F86557\" class=\"graphic graphic_table graphicRef86557 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/100,101\" class=\"abstract_t\">100,101</a>]. (See <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption#H71017118\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;, section on 'Early signs of severe reaction'</a>.)</p><p class=\"headingAnchor\" id=\"H57293602\"><span class=\"h2\">Cutaneous lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The skin lesions typically begin with ill-defined, coalescing, erythematous macules with purpuric centers, although many cases of <span class=\"nowrap\">SJS/TEN</span> may present with diffuse erythema (<a href=\"image.htm?imageKey=ALLRG%2F67632%7EDERM%2F68458%7EDERM%2F59418%7EALLRG%2F66134\" class=\"graphic graphic_picture graphicRef67632 graphicRef68458 graphicRef59418 graphicRef66134 \">picture 1A, 2A, 2C-D</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/102,103\" class=\"abstract_t\">102,103</a>]. The skin is often tender to the touch, and skin pain can be prominent and out of proportion to the cutaneous findings. </p><p>Lesions start on the face and thorax before spreading to other areas and are symmetrically distributed [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/104\" class=\"abstract_t\">104</a>]. The scalp is typically spared, and palms and soles are rarely involved [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/105,106\" class=\"abstract_t\">105,106</a>]. Atypical target lesions with darker centers may be present. As the disease progresses, vesicles and bullae form, and within days the skin begins to slough. </p><p>Nikolsky sign (ie, the ability to extend the area of superficial sloughing by applying gentle lateral pressure on the surface of the skin at an apparently uninvolved site) may be positive. The Asboe-Hansen sign or &quot;bulla spread sign&quot; (a lateral extension of bullae with pressure) may also be present. The ultimate appearance of the skin has been likened to that of extensive thermal injury [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/107\" class=\"abstract_t\">107</a>]. (See <a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters#H320493\" class=\"medical medical_review\">&quot;Approach to the patient with cutaneous blisters&quot;, section on 'Nikolsky sign'</a>.)</p><p class=\"headingAnchor\" id=\"H57293609\"><span class=\"h2\">Mucosal lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mucosal involvement occurs in approximately 90 percent of cases of <span class=\"nowrap\">SJS/TEN</span> and can precede or follow the skin eruption [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/108\" class=\"abstract_t\">108</a>]. Painful crusts and erosions may occur on any mucosal surface [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/100,109\" class=\"abstract_t\">100,109</a>].</p><p class=\"headingAnchor\" id=\"H398540402\"><span class=\"h3\">Oral</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The oral mucosa and the vermilion border are almost invariably involved, with painful hemorrhagic erosions covered with a grayish-white membrane (<a href=\"image.htm?imageKey=EM%2F73805%7EDERM%2F68682\" class=\"graphic graphic_picture graphicRef73805 graphicRef68682 \">picture 1C-D</a>). Stomatitis and mucositis lead to impaired oral intake with consequent malnutrition and dehydration.</p><p class=\"headingAnchor\" id=\"H398540408\"><span class=\"h3\">Ocular</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ocular involvement is reported in approximately 80 percent of patients. The most common change in the eyes is a severe conjunctivitis with a purulent discharge (<a href=\"image.htm?imageKey=DERM%2F93290\" class=\"graphic graphic_picture graphicRef93290 \">picture 1E</a>), but bullae may develop. Corneal ulceration is frequent, and anterior uveitis or panophthalmitis may occur. Pain and photophobia are accompanying symptoms. </p><p>A simple grading system based upon the presence of conjunctivitis, corneal or conjunctival epithelial defect, and pseudomembrane formation has been proposed to assess the severity of acute ocular involvement and guide the therapeutic choice [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/110\" class=\"abstract_t\">110</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No ocular involvement &ndash; 0 (none) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conjunctival hyperemia &ndash; 1 (mild) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Either ocular surface epithelial defect or pseudomembrane formation &ndash; 2 (severe) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Both ocular surface epithelial defect and pseudomembrane formation &ndash; 3 (very severe) </p><p/><p>The eye changes may regress completely, but at least 50 percent of patients have late eye sequelae including pain, dryness, and scarring with the development of synechiae between the eyelids and conjunctiva [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/111,112\" class=\"abstract_t\">111,112</a>]. (See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae#H20\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;, section on 'Long-term sequelae'</a>.)</p><p class=\"headingAnchor\" id=\"H398540414\"><span class=\"h3\">Urogenital</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urethritis develops in up to two-thirds of patients and may lead to urinary retention. Genital erosions are frequent. In women, vulvovaginal involvement may present with erosive and ulcerative vaginitis, vulvar bullae, vaginal synechiae, and may lead to long-term anatomic sequelae. These include labial and vaginal adhesions and stenosis, obstructed urinary stream and urinary retention, recurrent cystitis, or hematocolpos [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/113-117\" class=\"abstract_t\">113-117</a>]. Vulvovaginal adenosis (presence of metaplastic cervical or endometrial glandular epithelium in the vulva or vagina) also has been reported in women with <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/118-120\" class=\"abstract_t\">118-120</a>]. </p><p class=\"headingAnchor\" id=\"H398540420\"><span class=\"h3\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharyngeal mucosa is affected in nearly all patients; tracheal, bronchial, and esophageal membranes are less frequently involved [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/121,122\" class=\"abstract_t\">121,122</a>]. Intestinal involvement is rare [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/123\" class=\"abstract_t\">123</a>].</p><p class=\"headingAnchor\" id=\"H57293616\"><span class=\"h2\">Laboratory abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hematologic abnormalities, particularly anemia and lymphopenia, are common in <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/104\" class=\"abstract_t\">104</a>]. Eosinophilia is unusual; neutropenia is present in approximately one-third of patients and is correlated with a poor prognosis [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/104,124\" class=\"abstract_t\">104,124</a>]. However, the administration of systemic corticosteroids can cause demarginalization and mobilization of neutrophils into the circulation, and this may obscure neutropenia. </p><p>Hypoalbuminemia, electrolyte imbalance, and increased blood urea nitrogen and glucose may be noted in severe cases, due to massive transdermal fluid loss and hypercatabolic state. Serum urea nitrogen &gt;10 <span class=\"nowrap\">mmol/L</span> and glucose&nbsp;&gt;14 <span class=\"nowrap\">mmol/L</span> are considered markers of disease severity [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/125\" class=\"abstract_t\">125</a>]. Mild elevations in serum aminotransferase levels (two to three times the normal value) are present in approximately one-half of patients with TEN, while overt hepatitis occurs in approximately 10 percent [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/109\" class=\"abstract_t\">109</a>]. </p><p class=\"headingAnchor\" id=\"H57293623\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The acute phase of Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> lasts 8 to 12 days and is characterized by persistent fever, severe mucous membrane involvement, and epidermal sloughing that may be generalized and result in large, raw, painful areas of denuded skin. Re-epithelialization may begin after several days and typically requires two to four weeks [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/126\" class=\"abstract_t\">126</a>]. Skin that remained attached during the acute process may peel gradually, and nails may be shed. </p><p class=\"headingAnchor\" id=\"H171103\"><span class=\"h1\">COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In severe cases with extensive skin detachment, acute complications may include massive loss of fluids through the denuded skin, electrolyte imbalance, hypovolemic shock with renal failure, bacteremia, insulin resistance, hypercatabolic state, and multiple organ dysfunction syndrome. Abdominal compartment syndrome secondary to excessive replacement fluid therapy has been reported in a few patients [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/127\" class=\"abstract_t\">127</a>]. (See <a href=\"topic.htm?path=abdominal-compartment-syndrome-in-adults\" class=\"medical medical_review\">&quot;Abdominal compartment syndrome in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2266111040\"><span class=\"h2\">Infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> are at high risk of bacterial infection. Sepsis and septic shock, most often caused by <em>Staphylococcus aureus </em>and <em>Pseudomonas aeruginosa</em>, are the main causes of death in these patients. In a study of 179 patients with <span class=\"nowrap\">SJS/TEN,</span> bacteremia was detected in 48 (27 percent) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/128\" class=\"abstract_t\">128</a>]. The main pathogens implicated were <em>S. aureus</em>, <em>P. aeruginosa</em>, and Enterobacteriaceae organisms. The risk of bacteremia was higher in patients older than 40 years, in those with skin detachment on more than 30 percent of body surface area (BSA), and in those with greater than 10,000 white blood cell count. (See <a href=\"topic.htm?path=sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis\" class=\"medical medical_review\">&quot;Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H2281065386\"><span class=\"h2\">Pulmonary complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary complications (eg, pneumonia, interstitial pneumonitis) are frequent. Presenting symptoms include cough and elevated respiratory rate. Strict clinical surveillance is necessary for these patients, due to the risk of progression to acute respiratory distress syndrome. Acute respiratory failure requiring mechanical ventilation has been reported in approximately 25 percent of patients with <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/121\" class=\"abstract_t\">121</a>]. (See <a href=\"topic.htm?path=acute-respiratory-distress-syndrome-clinical-features-and-diagnosis-in-adults\" class=\"medical medical_review\">&quot;Acute respiratory distress syndrome: Clinical features and diagnosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H854083912\"><span class=\"h2\">Gastrointestinal complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal complications may result from epithelial necrosis of the esophagus, small bowel, or colon. Diarrhea, melena, small bowel ulcerations, colonic perforation, and small bowel intussusception have been reported in a few patients [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/129-132\" class=\"abstract_t\">129-132</a>]. </p><p class=\"headingAnchor\" id=\"H171450\"><span class=\"h1\">LONG-TERM SEQUELAE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Long-term sequelae of Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> are discussed separately. (See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae#H20\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;, section on 'Long-term sequelae'</a>.)</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">PATIENT EVALUATION AND DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H489653116\"><span class=\"h2\">Clinical findings and history</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no universally accepted diagnostic criteria for Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN),</span> and histologic findings are neither specific nor diagnostic.&nbsp;Despite these limitations, the diagnosis of SJS or TEN would be appropriate in a patient with the following clinical features [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/133\" class=\"abstract_t\">133</a>] (see <a href=\"#H57293557\" class=\"local\">'Clinical presentation'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A suggestive history of drug exposure or febrile illness. Drug exposure commonly precedes the onset of symptoms by one to four weeks (average 14 days), but re-exposure may result in onset of symptoms in as little as 48 hours [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/134\" class=\"abstract_t\">134</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A prodrome of acute-onset febrile illness and malaise.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A painful rash that progresses rapidly.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythematous macules, targetoid lesions, or diffuse erythema progressing to vesicles and bullae (<a href=\"image.htm?imageKey=ALLRG%2F67632\" class=\"graphic graphic_picture graphicRef67632 \">picture 1A</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Positive Nikolsky sign <span class=\"nowrap\">and/or</span> &quot;bulla spread sign.&quot;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral, ocular, <span class=\"nowrap\">and/or</span> genital mucositis with painful mucosal erosions (<a href=\"image.htm?imageKey=EM%2F73805%7EDERM%2F93290\" class=\"graphic graphic_picture graphicRef73805 graphicRef93290 \">picture 1C, 1E</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Necrosis and sloughing of the epidermis of varying degree (<a href=\"image.htm?imageKey=DERM%2F59418\" class=\"graphic graphic_picture graphicRef59418 \">picture 2C</a>).</p><p/><p class=\"headingAnchor\" id=\"H61178315\"><span class=\"h2\">Assessment of drug causality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients suspected to have <span class=\"nowrap\">SJS/TEN,</span> the identification of the causative drug is essential because early withdrawal of the offending agent may improve the prognosis [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/135\" class=\"abstract_t\">135</a>]. In addition, the identification of the culprit drug is of paramount importance to prevent re-exposure in patients recovering from <span class=\"nowrap\">SJS/TEN</span>. </p><p>The assessment of drug causality is based upon detailed history and clinical judgement. Information about the drugs that are most frequently associated with <span class=\"nowrap\">SJS/TEN</span> is helpful (<a href=\"image.htm?imageKey=DERM%2F91163\" class=\"graphic graphic_table graphicRef91163 \">table 2</a>). An algorithm of drug causality for epidermal necrolysis (ALDEN) has been developed as a tool for rapid assessment of drug causality in patients presenting with <span class=\"nowrap\">SJS/TEN,</span> particularly in those exposed to multiple medications [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/15\" class=\"abstract_t\">15</a>]. Each potentially offending drug is assigned a score from -11 to 10 based upon six parameters (<a href=\"image.htm?imageKey=DERM%2F93517\" class=\"graphic graphic_table graphicRef93517 \">table 5</a>): </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Time delay from initial drug intake to onset of reaction</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Probability of drug presence in the body on the index day</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A previous history of exposure to the same drug, with or without reaction</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of the drug beyond the progression phase of the disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug notoriety as a cause of <span class=\"nowrap\">SJS/TEN</span> based upon previous studies</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence or absence of other etiologic causes</p><p/><p>The score is categorized as very probable (&ge;6), probable (4 to 5), possible (2 to 3), unlikely (0 to 1), and very unlikely (&le;0). </p><p class=\"headingAnchor\" id=\"H3080720\"><span class=\"h2\">Assessment of severity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The severity and prognosis of <span class=\"nowrap\">SJS/TEN</span> depends upon the amount of skin detachment or &quot;detachable&quot; skin (ie, skin with positive Nikolsky sign). The extent of epidermal detachments should be estimated and recorded as the percentage of the body surface area (BSA) involved.</p><p>The correct evaluation of the extent of lesions may be difficult in areas with spotty lesions. It is useful to remember that in both children and adults the surface of the patient's hand, including palm and fingers, corresponds to approximately 1 percent of the total BSA. (See <a href=\"topic.htm?path=classification-of-burn-injury#H16\" class=\"medical medical_review\">&quot;Classification of burn injury&quot;, section on 'Extent of burn injury'</a>.)</p><p>The prognosis of individual patients can be rapidly evaluated in the early stages of disease by applying a prognostic scoring system called SCORTEN, based upon seven clinical and laboratory variables (<a href=\"image.htm?imageKey=ALLRG%2F66897\" class=\"graphic graphic_table graphicRef66897 \">table 6</a>) [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/125\" class=\"abstract_t\">125</a>]. (See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae#H150140096\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;, section on 'SCORTEN score'</a>.)</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Skin biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A skin biopsy for routine histopathologic examination and possibly direct immunofluorescence is useful in confirming the diagnosis and excluding other conditions that may mimic <span class=\"nowrap\">SJS/TEN</span>. An appropriate sample may be obtained by performing a large (&gt;4 mm) punch biopsy or a deep shave biopsy (&quot;saucerization&quot;).</p><p>In the early stages of disease, apoptotic keratinocytes are scattered in the basal layer of the epidermis, and there is a perivascular, mononuclear, inflammatory infiltrate in the papillary dermis composed primarily of T lymphocytes [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. This infiltrate is not diagnostic and may be seen in a wide variety of conditions, including a simple drug-induced exanthem. As the lesions progress, frank subepidermal bullae develop, with full-thickness epidermal necrosis (<a href=\"image.htm?imageKey=DERM%2F93209\" class=\"graphic graphic_picture graphicRef93209 \">picture 3</a>). </p><p>Direct immunofluorescence is always negative.</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h2\">Laboratory and imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The laboratory and imaging evaluation of patients presenting with <span class=\"nowrap\">SJS/TEN</span> includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count with differential, metabolic panel (ie, glucose, electrolytes, blood urea nitrogen, creatinine, calcium, total protein, albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase), erythrocyte sedimentation rate, and C-reactive protein.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacterial and fungal cultures should be performed from blood, wounds, and mucosal lesions. Because of the high risk of bacterial superinfection and sepsis in these patients, cultures should be repeated throughout the acute phase of the disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In children, polymerase chain reaction <span class=\"nowrap\">and/or</span> serologies for <em>M. pneumoniae</em> infection should be obtained in the early stage of disease and three weeks later. (See <a href=\"topic.htm?path=mycoplasma-pneumoniae-infection-in-children#H15\" class=\"medical medical_review\">&quot;Mycoplasma pneumoniae infection in children&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A chest radiograph should be obtained in all patients, due to high risk of pneumonia and interstitial pneumonitis. (See <a href=\"#H2281065386\" class=\"local\">'Pulmonary complications'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H30\"><span class=\"h2\">Investigational tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Candidate serum markers of <span class=\"nowrap\">SJS/TEN,</span> including soluble Fas ligand, soluble CD40 ligand, granulysin, interleukin (IL)-15, and high-mobility group box 1 protein (HMGB1, a nonhistone nuclear protein released by necrotic and apoptotic cells), have been evaluated in a few small studies [<a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/96,97,136-138\" class=\"abstract_t\">96,97,136-138</a>]. However, further studies are necessary to determine whether these markers may be helpful in the early diagnosis of <span class=\"nowrap\">SJS/TEN</span>. (See <a href=\"#H22\" class=\"local\">'Pathogenesis'</a> above.)</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythema multiforme</strong> &ndash; Erythema multiforme usually presents with typical target lesions or raised, atypical, targetoid lesions that are predominantly located on the extremities (<a href=\"image.htm?imageKey=DERM%2F79955\" class=\"graphic graphic_picture graphicRef79955 \">picture 4</a>). Bullae and epidermal detachment are usually limited and involve less than 10 percent of the body surface area (BSA) (<a href=\"image.htm?imageKey=PEDS%2F77983\" class=\"graphic graphic_table graphicRef77983 \">table 1</a>). In contrast with <span class=\"nowrap\">SJS/TEN,</span> erythema multiforme is associated with infection with herpes simplex virus in approximately 90 percent of cases and only rarely with drugs. (See <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of erythema multiforme&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythroderma and erythematous drug eruptions</strong> &ndash; The generalized and symmetric, maculopapular erythema of a drug eruption can mimic early <span class=\"nowrap\">SJS/TEN</span>. However, exanthematous drug eruptions lack mucosal involvement and the prominent skin pain of TEN. Histology shows only a mild interface dermatitis with a perivascular, inflammatory infiltrate of lymphocytes, neutrophils, and eosinophils. (See <a href=\"topic.htm?path=erythroderma-in-adults\" class=\"medical medical_review\">&quot;Erythroderma in adults&quot;</a> and <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Acute generalized exanthematous pustulosis</strong> &ndash; Severe cases of acute generalized exanthematous pustulosis (AGEP) may be difficult to differentiate from <span class=\"nowrap\">SJS/TEN</span> (<a href=\"image.htm?imageKey=ALLRG%2F56807\" class=\"graphic graphic_picture graphicRef56807 \">picture 5</a>). AGEP typically develops within a few days of exposure to the offending drug, most often a beta-lactam antibiotic, and resolves without treatment in one to two weeks after drug discontinuation. The histologic hallmark of AGEP is a spongiform, subcorneal, <span class=\"nowrap\">and/or</span> intraepidermal pustule (<a href=\"image.htm?imageKey=ALLRG%2F56807\" class=\"graphic graphic_picture graphicRef56807 \">picture 5</a>). (See <a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">&quot;Acute generalized exanthematous pustulosis (AGEP)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Generalized bullous fixed drug eruption</strong> &ndash; Generalized bullous fixed drug eruption is an extremely rare form of fixed drug eruption characterized by widespread red or brown macules or plaques with overlying, large, flaccid bullae (<a href=\"image.htm?imageKey=DERM%2F86645\" class=\"graphic graphic_picture graphicRef86645 \">picture 6</a>). In contrast with <span class=\"nowrap\">SJS/TEN,</span> mucosal involvement is usually absent. Resolution generally occurs in one to two weeks after drug discontinuation. (See <a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">&quot;Fixed drug eruption&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Phototoxic eruptions</strong> &ndash; Severe phototoxic eruptions may be confused with <span class=\"nowrap\">SJS/TEN</span>. Important clues to the correct diagnosis include recent sun exposure, known phototoxic properties of certain medications, and location of the lesions on sun-exposed areas. (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Staphylococcal scalded skin syndrome</strong> &ndash; Staphylococcal scalded skin syndrome (SSSS) is caused by epidermolytic toxins produced by certain strains of staphylococci and is usually seen in neonates and young children. SSSS presents with generalized erythema rapidly followed by the development of flaccid blisters and desquamation (<a href=\"image.htm?imageKey=DERM%2F72261\" class=\"graphic graphic_picture graphicRef72261 \">picture 7</a>). The mucous membranes are not involved. Histology reveals sloughing of only the upper layers of the epidermis, in contrast with the subepidermal split with full-thickness epidermal necrosis observed in <span class=\"nowrap\">SJS/TEN</span>. (See <a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant#H8\" class=\"medical medical_review\">&quot;Vesiculopustular and bullous lesions in the newborn and infant&quot;, section on 'Staphylococcal scalded skin syndrome'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Paraneoplastic pemphigus</strong> &ndash; Paraneoplastic pemphigus is a rare disorder that can represent the initial presentation of a malignancy or occur in a patient with a known neoplastic process, such as non-Hodgkin lymphoma in adults or Castleman's disease in children. Patients may develop severe mucocutaneous disease with ocular and oral blisters and skin lesions (<a href=\"image.htm?imageKey=DERM%2F67265%7EDERM%2F62146%7EDERM%2F59594\" class=\"graphic graphic_picture graphicRef67265 graphicRef62146 graphicRef59594 \">picture 8A-C</a>). (See <a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">&quot;Paraneoplastic pemphigus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Linear IgA bullous dermatosis</strong> &ndash; Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease that may mimic TEN (<a href=\"image.htm?imageKey=DERM%2F64559\" class=\"graphic graphic_picture graphicRef64559 \">picture 9</a>). Histology reveals a subepidermal blister with an underlying, neutrophil-predominant, dermal infiltrate. Direct immunofluorescence shows linear deposits of IgA along the basement membrane. (See <a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">&quot;Linear IgA bullous dermatosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H746541189\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Stevens-Johnson syndrome and toxic epidermal necrolysis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Stevens-Johnson syndrome and toxic epidermal necrolysis (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions, most commonly triggered by medications, characterized by extensive necrosis and detachment of the epidermis. Cases with less than 10 percent epidermal involvement are classified as SJS; those with 30 percent or more involvement are classified as TEN, and cases with 10 to 30 percent involvement are considered overlap <span class=\"nowrap\">SJS/TEN</span>. However, we use the term <span class=\"nowrap\">&quot;SJS/TEN&quot;</span> to refer collectively to SJS, TEN, and <span class=\"nowrap\">SJS/TEN</span> overlap syndrome. (See <a href=\"#H1\" class=\"local\">'Introduction and terminology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medications are the leading trigger of <span class=\"nowrap\">SJS/TEN</span> in both adults and children. <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">Allopurinol</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, aromatic anticonvulsants, antibacterial sulfonamides, and &quot;oxicam&quot; or COX-2 inhibitor nonsteroidal anti-inflammatory drugs (NSAIDS) are most commonly implicated (<a href=\"image.htm?imageKey=DERM%2F91163\" class=\"graphic graphic_table graphicRef91163 \">table 2</a>). <em>Mycoplasma pneumoniae</em> infection is the next most common trigger of <span class=\"nowrap\">SJS/TEN,</span> particularly in children. (See <a href=\"#H6\" class=\"local\">'Etiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors for <span class=\"nowrap\">SJS/TEN</span> include human immunodeficiency virus (HIV) infection, genetic factors, concomitant viral infections, underlying autoimmune diseases, and, possibly, physical factors. (See <a href=\"#H18\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">SJS/TEN</span> begins with a prodrome of fever and influenza-like symptoms one to three days before the development of mucocutaneous and skin lesions. The cutaneous eruption typically starts with ill-defined, coalescing, erythematous macules with atypical target lesions (<a href=\"image.htm?imageKey=ALLRG%2F67632%7EDERM%2F68458%7EDERM%2F59418%7EALLRG%2F66134\" class=\"graphic graphic_picture graphicRef67632 graphicRef68458 graphicRef59418 graphicRef66134 \">picture 1A, 2A, 2C-D</a>). As the disease progresses, vesicles and bullae form, and within days the skin begins to slough. Mucosal involvement occurs in approximately 90 percent of cases of <span class=\"nowrap\">SJS/TEN</span> and can precede or follow the skin eruption. (See <a href=\"#H57293557\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In severe cases with extensive skin detachment, acute complications may include massive loss of fluids and electrolyte imbalance, hypovolemic shock with renal failure, bacteremia, insulin resistance, hypercatabolic state, and multiple organ dysfunction syndrome. (See <a href=\"#H171103\" class=\"local\">'Complications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of <span class=\"nowrap\">SJS/TEN</span> is based upon clinical and histologic findings in a patient with a history of antecedent drug exposure or febrile illness. Histologic findings on skin biopsy are supportive but not independently diagnostic. (See <a href=\"#H27\" class=\"local\">'Patient evaluation and diagnosis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H3407628648\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We are saddened by the death of Milton H Nirken, MD, who passed away in August 2017. UpToDate wishes to acknowledge Dr. Nirken's past work as an author for this topic.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">Stern RS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done. J Invest Dermatol 2017; 137:1004.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24:726.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49:769.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Strom BL, Carson JL, Halpern AC, et al. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991; 10:565.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126:43.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126:37.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Sch&ouml;pf E, St&uuml;hmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127:839.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Frey N, Jossi J, Bodmer M, et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis&nbsp;in the UK. J Invest Dermatol 2017; 137:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135:6.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017; 76:811.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol 2012; 13:49.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Gillis NK, Hicks JK, Bell GC, et al. Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in&nbsp;a&nbsp;Large Cancer Patient Cohort. J Invest Dermatol 2017; 137:2021.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133:1197.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58:25.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123:e297.</a></li><li class=\"breakAll\">www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm363519.htm (Accessed on August 05, 2013).</li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Hwang S, Woo Y, Kim M, Park HJ. Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma. Int J Dermatol 2017; 56:e35.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Jadhav P, Rogers JE, Shroff R. A Case Report-Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine. J Gastrointest Cancer 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Doesch J, Debus D, Meyer C, et al. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer 2016; 95:35.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Bell&oacute;n T, Lerma V, Gonz&aacute;lez-Valle O, et al. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol 2016; 174:621.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Madabhavi I, Revannasiddaiah S, Patel A, Anand A. Toxic epidermal necrolysis with the use of tamoxifen. BMJ Case Rep 2015; 2015.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017; 41:125.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017; 44:381.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010; 85:131.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child 2013; 98:998.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Khalaf D, Toema B, Dabbour N, Jehani F. Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis. Mediterr J Hematol Infect Dis 2011; 3:e2011004.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015; 72:239.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol 2015; 29:595.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges 2012; 10:740.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Olson D, Watkins LK, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome. Pediatrics 2015; 136:e386.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Watkins LKF, Olson D, Diaz MH, et al. Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome. Pediatr Infect Dis J 2017; 36:564.</a></li><li class=\"breakAll\">www.cdc.gov/ncird/div/DBD/newsletters/2014/fall/sjs-outbreak.html (Accessed on August 20, 2015).</li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Chowdhury AD, Oda M, Markus AF, et al. Herbal medicine induced Stevens-Johnson syndrome: a case report. Int J Paediatr Dent 2004; 14:204.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Ball R, Ball LK, Wise RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20:219.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Oda T, Sawada Y, Okada E, et al. Stevens-Johnson Syndrome After Influenza Vaccine Injection. J Investig Allergol Clin Immunol 2017; 27:274.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Haddad C, Chosidow O, Valeyrie-Allanore L, et al. Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. J Invest Dermatol 2017; 137:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Boull CL, Hylwa SA, Sajic D, et al. Toxic Epidermal Necrolysis in Recessive Dystrophic Epidermolysis Bullosa following Bone Marrow Transplantation. J Pediatr 2016; 173:242.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Macedo FI, Faris J, Lum LG, et al. Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management. J Burn Care Res 2014; 35:e431.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Hilgendorf I, Casper J, Sviland L, et al. Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39:245.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol 2014; 37:506.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Dietrich A, Kawakubo Y, Rzany B, et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4:313.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Wolkenstein P, Carri&egrave;re V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83:1.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Yang C, Mosam A, Mankahla A, et al. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4&#8314; T cells. J Am Acad Dermatol 2014; 70:1096.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Borgiani P, Di Fusco D, Erba F, et al. HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. Eur J Clin Pharmacol 2014; 70:275.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Carr DF, Bourgeois S, Chaponda M, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother 2017; 72:1152.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients. Eur Rev Med Pharmacol Sci 2007; 11:269.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25:225.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol 2016; 136:1387.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149:1025.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011; 12:118.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Shen Y, Nicoletti P, Floratos A, et al. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J 2012; 12:96.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Li X, Yu K, Mei S, et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. Drug Res (Stuttg) 2015; 65:107.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Wang Q, Sun S, Xie M, et al. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A meta-analysis. Epilepsy Res 2017; 135:19.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Khor AH, Lim KS, Tan CT, et al. HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. Pharmacogenet Genomics 2017; 27:275.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Genin E, Chen DP, Hung SI, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14:281.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Shi YW, Min FL, Zhou D, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology 2017; 88:2183.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics 2017; 27:429.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Saksit N, Tassaneeyakul W, Nakkam N, et al. Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 2017; 27:255.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.</a></li><li class=\"breakAll\">www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150841.htm (Accessed on December 12, 2007).</li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55:496.</a></li><li class=\"breakAll\">www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500130391.pdf (Accessed on September 26, 2017).</li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93:153.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Manuyakorn W, Siripool K, Kamchaisatian W, et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Pediatr Allergy Immunol 2013; 24:299.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014; 312:525.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Tassaneeyakul W, Prabmeechai N, Sukasem C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 2016; 26:225.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/75\" class=\"nounderline abstract_t\">Ueta M, Sotozono C, Inatomi T, et al. Association of IL4R polymorphisms with Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120:1457.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/76\" class=\"nounderline abstract_t\">Ueta M, Sotozono C, Inatomi T, et al. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications. Invest Ophthalmol Vis Sci 2008; 49:1809.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Ueta M, Sotozono C, Nakano M, et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol 2010; 126:1218.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2013; 13:60.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/79\" class=\"nounderline abstract_t\">Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev 2006; 5:160.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol 2012; 166:575.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Yildirim Cetin G, Sayar H, Ozkan F, et al. A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. Lupus 2013; 22:839.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/83\" class=\"nounderline abstract_t\">Sommers KR, Kong KM, Bui DT, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs 2003; 14:659.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1:349.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Duncan KO, Tigelaar RE, Bolognia JL. Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. J Am Acad Dermatol 1999; 40:493.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129:466.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/89\" class=\"nounderline abstract_t\">Roujeau JC, Bricard G, Nicolas JF. Drug-induced epidermal necrolysis: Important new piece to end the puzzle. J Allergy Clin Immunol 2011; 128:1277.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/90\" class=\"nounderline abstract_t\">Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128:1266.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/91\" class=\"nounderline abstract_t\">Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109:9959.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/92\" class=\"nounderline abstract_t\">Adam J, Wuillemin N, Watkins S, et al. Abacavir induced T cell reactivity from drug na&iuml;ve individuals shares features of allo-immune responses. PLoS One 2014; 9:e95339.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/93\" class=\"nounderline abstract_t\">Lee HY, Chung WH. Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol 2013; 13:330.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/94\" class=\"nounderline abstract_t\">Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/95\" class=\"nounderline abstract_t\">Morel E, Escamochero S, Caba&ntilde;as R, et al. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 2010; 125:703.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/96\" class=\"nounderline abstract_t\">Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol 2017; 137:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/97\" class=\"nounderline abstract_t\">Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008; 122:992.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/98\" class=\"nounderline abstract_t\">Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/99\" class=\"nounderline abstract_t\">de Araujo E, Dessirier V, Lapr&eacute;e G, et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20:107.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/100\" class=\"nounderline abstract_t\">Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/101\" class=\"nounderline abstract_t\">Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 2005; 209:201.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/102\" class=\"nounderline abstract_t\">Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69:173.e1.</a></li><li class=\"breakAll\">Valeyrie-Allanore L, Roujeau JC. Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS (Eds), McGrow-Hill Medical, New York 2012. Vol 1, p.439.</li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/104\" class=\"nounderline abstract_t\">Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/105\" class=\"nounderline abstract_t\">Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13:623.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/106\" class=\"nounderline abstract_t\">Revuz J, Roujeau JC, Guillaume JC, et al. Treatment of toxic epidermal necrolysis. Cr&eacute;teil's experience. Arch Dermatol 1987; 123:1156.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/107\" class=\"nounderline abstract_t\">LYELL A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68:355.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/108\" class=\"nounderline abstract_t\">Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94:419.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/109\" class=\"nounderline abstract_t\">Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/110\" class=\"nounderline abstract_t\">Sotozono C, Ueta M, Nakatani E, et al. Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Am J Ophthalmol 2015; 160:228.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/111\" class=\"nounderline abstract_t\">Morales ME, Purdue GF, Verity SM, et al. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150:505.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/112\" class=\"nounderline abstract_t\">Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145:157.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/113\" class=\"nounderline abstract_t\">Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91:283.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/114\" class=\"nounderline abstract_t\">Hart R, Minto C, Creighton S. Vaginal adhesions caused by Stevens-Johnson syndrome. J Pediatr Adolesc Gynecol 2002; 15:151.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/115\" class=\"nounderline abstract_t\">Wilson EE, Malinak LR. Vulvovaginal sequelae of Stevens-Johnson syndrome and their management. Obstet Gynecol 1988; 71:478.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/116\" class=\"nounderline abstract_t\">de Jesus LE, Dekermacher S, Manh&atilde;es CR, et al. Acquired labial sinechiae and hydrocolpos secondary to Stevens-Johnson syndrome. Urology 2012; 80:919.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/117\" class=\"nounderline abstract_t\">Pliskow S. Severe gynecologic sequelae of Stevens-Johnson syndrome and toxic epidermal necrolysis caused by ibuprofen: a case report. J Reprod Med 2013; 58:354.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/118\" class=\"nounderline abstract_t\">Emberger M, Lanschuetzer CM, Laimer M, et al. Vaginal adenosis induced by Stevens-Johnson syndrome. J Eur Acad Dermatol Venereol 2006; 20:896.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/119\" class=\"nounderline abstract_t\">Marquette GP, Su B, Woodruff JD. Introital adenosis associated with Stevens-Johnson syndrome. Obstet Gynecol 1985; 66:143.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/120\" class=\"nounderline abstract_t\">No&euml;l JC, Buxant F, Fayt I, et al. Vulval adenosis associated with toxic epidermal necrolysis. Br J Dermatol 2005; 153:457.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/121\" class=\"nounderline abstract_t\">de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42:118.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/122\" class=\"nounderline abstract_t\">Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23:1237.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/123\" class=\"nounderline abstract_t\">Jha AK, Goenka MK. Colonic involvement in Stevens-Johnson syndrome: a rare entity. Dig Endosc 2012; 24:382.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/124\" class=\"nounderline abstract_t\">Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984; 120:721.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/125\" class=\"nounderline abstract_t\">Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/126\" class=\"nounderline abstract_t\">Jordan MH, Lewis MS, Jeng JG, Rees JM. Treatment of toxic epidermal necrolysis by burn units: another market or another threat? J Burn Care Rehabil 1991; 12:579.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/127\" class=\"nounderline abstract_t\">Struck MF, Illert T, Schmidt T, et al. Secondary abdominal compartment syndrome in patients with toxic epidermal necrolysis. Burns 2012; 38:562.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/128\" class=\"nounderline abstract_t\">de Prost N, Ingen-Housz-Oro S, Duong Ta, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89:28.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/129\" class=\"nounderline abstract_t\">Bouziri A, Khaldi A, Hamdi A, et al. Toxic epidermal necrolysis complicated by small bowel intussusception: a case report. J Pediatr Surg 2011; 46:e9.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/130\" class=\"nounderline abstract_t\">Chosidow O, Delchier JC, Chaumette MT, et al. Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 1991; 337:928.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/131\" class=\"nounderline abstract_t\">Sakai N, Yoshizawa Y, Amano A, et al. Toxic epidermal necrolysis complicated by multiple intestinal ulcers. Int J Dermatol 2008; 47:180.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/132\" class=\"nounderline abstract_t\">Carter FM, Mitchell CK. Toxic epidermal necrolysis--an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum 1993; 36:773.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/133\" class=\"nounderline abstract_t\">Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013; 69:187.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/134\" class=\"nounderline abstract_t\">Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006; 55:27.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/135\" class=\"nounderline abstract_t\">Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136:323.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/136\" class=\"nounderline abstract_t\">Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009; 151:514.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/137\" class=\"nounderline abstract_t\">Caproni M, Antiga E, Parodi A, et al. Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006; 154:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis/abstract/138\" class=\"nounderline abstract_t\">Nakajima S, Watanabe H, Tohyama M, et al. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 2011; 147:1110.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2091 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H32\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION AND TERMINOLOGY</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">EPIDEMIOLOGY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">ETIOLOGY</a><ul><li><a href=\"#H57294570\" id=\"outline-link-H57294570\">Drugs</a></li><li><a href=\"#H57294577\" id=\"outline-link-H57294577\">Mycoplasma pneumoniae infection</a></li><li><a href=\"#H57294584\" id=\"outline-link-H57294584\">Other</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">RISK FACTORS</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">Human immunodeficiency virus infection</a></li><li><a href=\"#H4044226447\" id=\"outline-link-H4044226447\">Malignancy</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Genetic factors</a><ul><li><a href=\"#H2115552208\" id=\"outline-link-H2115552208\">- HLA types</a><ul><li><a href=\"#H1356230396\" id=\"outline-link-H1356230396\">Genetic screening</a></li></ul></li><li><a href=\"#H2273738131\" id=\"outline-link-H2273738131\">- Genetic polymorphisms</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">Other factors</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">PATHOGENESIS</a><ul><li><a href=\"#H54377763\" id=\"outline-link-H54377763\">Mediators of keratinocyte apoptosis</a><ul><li><a href=\"#H23\" id=\"outline-link-H23\">- Granulysin</a></li><li><a href=\"#H603157469\" id=\"outline-link-H603157469\">- Interleukin-15</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">- Other factors</a></li></ul></li></ul></li><li><a href=\"#H61178230\" id=\"outline-link-H61178230\">HISTOPATHOLOGY</a></li><li><a href=\"#H57293557\" id=\"outline-link-H57293557\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H57293595\" id=\"outline-link-H57293595\">Prodrome</a></li><li><a href=\"#H57293602\" id=\"outline-link-H57293602\">Cutaneous lesions</a></li><li><a href=\"#H57293609\" id=\"outline-link-H57293609\">Mucosal lesions</a><ul><li><a href=\"#H398540402\" id=\"outline-link-H398540402\">- Oral</a></li><li><a href=\"#H398540408\" id=\"outline-link-H398540408\">- Ocular</a></li><li><a href=\"#H398540414\" id=\"outline-link-H398540414\">- Urogenital</a></li><li><a href=\"#H398540420\" id=\"outline-link-H398540420\">- Other</a></li></ul></li><li><a href=\"#H57293616\" id=\"outline-link-H57293616\">Laboratory abnormalities</a></li></ul></li><li><a href=\"#H57293623\" id=\"outline-link-H57293623\">CLINICAL COURSE</a></li><li><a href=\"#H171103\" id=\"outline-link-H171103\">COMPLICATIONS</a><ul><li><a href=\"#H2266111040\" id=\"outline-link-H2266111040\">Infections</a></li><li><a href=\"#H2281065386\" id=\"outline-link-H2281065386\">Pulmonary complications</a></li><li><a href=\"#H854083912\" id=\"outline-link-H854083912\">Gastrointestinal complications</a></li></ul></li><li><a href=\"#H171450\" id=\"outline-link-H171450\">LONG-TERM SEQUELAE</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">PATIENT EVALUATION AND DIAGNOSIS</a><ul><li><a href=\"#H489653116\" id=\"outline-link-H489653116\">Clinical findings and history</a></li><li><a href=\"#H61178315\" id=\"outline-link-H61178315\">Assessment of drug causality</a></li><li><a href=\"#H3080720\" id=\"outline-link-H3080720\">Assessment of severity</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">Skin biopsy</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">Laboratory and imaging studies</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">Investigational tests</a></li></ul></li><li><a href=\"#H31\" id=\"outline-link-H31\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H746541189\" id=\"outline-link-H746541189\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H4251711\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H3407628648\" id=\"outline-link-H3407628648\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/2091|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/67632\" class=\"graphic graphic_picture\">- Cutaneous changes of Stevens-Johnson syndrome (SJS)</a></li><li><a href=\"image.htm?imageKey=EM/76141\" class=\"graphic graphic_picture\">- Cutaneous findings of Stevens-Johnson syndrome</a></li><li><a href=\"image.htm?imageKey=EM/73805\" class=\"graphic graphic_picture\">- Mucosal changes in Stevens-Johnson syndrome</a></li><li><a href=\"image.htm?imageKey=DERM/68458\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis - back</a></li><li><a href=\"image.htm?imageKey=DERM/82150\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis - bullae</a></li><li><a href=\"image.htm?imageKey=DERM/59418\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis - abdomen</a></li><li><a href=\"image.htm?imageKey=ALLRG/66134\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis (TEN)</a></li><li><a href=\"image.htm?imageKey=DERM/93209\" class=\"graphic graphic_picture\">- Stevens-Johnson syndrome/toxic epidermal necrolysis histology</a></li><li><a href=\"image.htm?imageKey=DERM/68682\" class=\"graphic graphic_picture\">- Stevens-Johnson syndrome (SJS)</a></li><li><a href=\"image.htm?imageKey=DERM/93290\" class=\"graphic graphic_picture\">- Stevens-Johnson syndrome/toxic epidermal necrolysis eyes</a></li><li><a href=\"image.htm?imageKey=DERM/79955\" class=\"graphic graphic_picture\">- Erythema multiforme target lesion</a></li><li><a href=\"image.htm?imageKey=ALLRG/56807\" class=\"graphic graphic_picture\">- Acute generalized exanthematous pustulosis (AGEP)</a></li><li><a href=\"image.htm?imageKey=DERM/86645\" class=\"graphic graphic_picture\">- Bullous fixed drug eruption</a></li><li><a href=\"image.htm?imageKey=DERM/72261\" class=\"graphic graphic_picture\">- Staphylococcal scalded skin syndrome - trunk</a></li><li><a href=\"image.htm?imageKey=DERM/67265\" class=\"graphic graphic_picture\">- Paraneoplastic pemphigus bullae</a></li><li><a href=\"image.htm?imageKey=DERM/62146\" class=\"graphic graphic_picture\">- Paraneoplastic pemphigus toxic epidermal necrolysis-like</a></li><li><a href=\"image.htm?imageKey=DERM/59594\" class=\"graphic graphic_picture\">- Paraneoplastic pemphigus oral findings</a></li><li><a href=\"image.htm?imageKey=DERM/64559\" class=\"graphic graphic_picture\">- Linear IgA bullous dermatosis - toxic epidermal necrolysis-like</a></li></ul></li><li><div id=\"DERM/2091|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/77983\" class=\"graphic graphic_table\">- Erythema multiforme and SJS-TEN skin findings</a></li><li><a href=\"image.htm?imageKey=DERM/91163\" class=\"graphic graphic_table\">- Drugs associated with SJS-TEN</a></li><li><a href=\"image.htm?imageKey=ALLRG/76186\" class=\"graphic graphic_table\">- SJS/TEN risk HLA type</a></li><li><a href=\"image.htm?imageKey=DERM/86557\" class=\"graphic graphic_table\">- Clinical and laboratory features of severe drug eruptions</a></li><li><a href=\"image.htm?imageKey=DERM/93517\" class=\"graphic graphic_table\">- ALDEN algorithm</a></li><li><a href=\"image.htm?imageKey=ALLRG/66897\" class=\"graphic graphic_table\">- Toxic epidermal necrolysis SCORTEN criteria</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=abdominal-compartment-syndrome-in-adults\" class=\"medical medical_review\">Abdominal compartment syndrome in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors\" class=\"medical medical_review\">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">Acute generalized exanthematous pustulosis (AGEP)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-respiratory-distress-syndrome-clinical-features-and-diagnosis-in-adults\" class=\"medical medical_review\">Acute respiratory distress syndrome: Clinical features and diagnosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-cutaneous-blisters\" class=\"medical medical_review\">Approach to the patient with cutaneous blisters</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-of-burn-injury\" class=\"medical medical_review\">Classification of burn injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-allergy-pathogenesis\" class=\"medical medical_review\">Drug allergy: Pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythroderma-in-adults\" class=\"medical medical_review\">Erythroderma in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">Exanthematous (maculopapular) drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">Fixed drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichenoid-drug-eruption-drug-induced-lichen-planus\" class=\"medical medical_review\">Lichenoid drug eruption (drug-induced lichen planus)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">Linear IgA bullous dermatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycoplasma-pneumoniae-infection-in-children\" class=\"medical medical_review\">Mycoplasma pneumoniae infection in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">Paraneoplastic pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-graft-versus-host-disease\" class=\"medical medical_review\">Pathogenesis of graft-versus-host disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">Pathogenesis, clinical features, and diagnosis of erythema multiforme</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-the-basics\" class=\"medical medical_basics\">Patient education: Stevens-Johnson syndrome and toxic epidermal necrolysis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacologic-urate-lowering-therapy-and-treatment-of-tophi-in-patients-with-gout\" class=\"medical medical_review\">Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis\" class=\"medical medical_review\">Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis\" class=\"medical medical_society_guidelines\">Society guideline links: Stevens-Johnson syndrome and toxic epidermal necrolysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant\" class=\"medical medical_review\">Vesiculopustular and bullous lesions in the newborn and infant</a></li></ul></div></div>","javascript":null}